

ÅRSREDOVISNING

för

CJ Scandinavian Seaview Consulting AB

Org.nr. 559231-1657

Styrelsen får härmed avlämna årsredovisning för räkenskapsåret 2024-01-01 - 2024-12-31

Undertecknad styrelseledamot i CJ Scandinavian Seaview Consulting AB intygar härmed, dels att denna kopia av årsredovisningen överensstämmer med originalet, dels att resultat- och balansräkning fastställts på årsstämman den 2 juni 2025. Stämman beslöt tillika godkänna styrelsens förslag till vinstdisposition.

Lund 2025-06-02

Chenjia Xu



2025061014684

ÅRSREDOVISNING
för
CJ Scandinavian Seaview Consulting AB
Org.nr. 559231-1657

Styrelsen får härmed avlämna årsredovisning för räkenskapsåret 2024-01-01 - 2024-12-31

CJ Scandinavian Seaview Consulting AB

Org.nr. 559231-1657

FÖRVALTNINGSBERÄTTELSE

Årsredovisningen är upprättad i svenska kronor, SEK.

Verksamheten**Allmänt om verksamheten**

Företagets verksamhet är att bedriva konsulttjänster inom industriell marknadsföring, varumärkesstrategi samt konsumentvaruhandel inom mat, dryck, kosmetika samt mode.

Företagets säte är Lund.

Flerårsöversikt

Beloppen i Flerårsöversikt visas i KSEK

	2024	2023	2022	2021
Nettoomsättning	200	807	2 396	1 569
Resultat efter finansiella poster	-1 407	638	2 194	1 566
Soliditet (%)	92	93	80	76

Definitioner av nyckeltal, se noter

Resultatdisposition

Medel att disponera:

Balanserat resultat	3 594 639
Årets resultat	<u>-1 453 344</u>
	2 141 295

Förslag till disposition:

Balanseras i ny räkning	<u>2 141 295</u>
	2 141 295

Beträffande bolagets resultat och ställning i övrigt hänvisas till efterföljande resultat- och balansräkningar med tillhörande noter.

CJ Scandinavian Seaview Consulting AB

Org.nr. 559231-1657

RESULTATRÄKNING

	Not	2024-01-01 2024-12-31	2023-01-01 2023-12-31
Rörelseintäkter, lagerförändringar m.m.			
Nettoomsättning		200 000	807 498
Summa rörelseintäkter, lagerförändringar m.m.		200 000	807 498
Rörelsekostnader			
Råvaror och förnödenheter		0	-6 485
Övriga externa kostnader		-1 250	-146 006
Personalkostnader		0	-12 443
Summa rörelsekostnader		-1 250	-164 934
Rörelseresultat		198 750	642 564
Finansiella poster			
Resultat från övriga finansiella anläggningstillgångar		-600 019	0
Övriga ränteintäkter och liknande resultatposter		4 341	0
Nedskrivningar av finansiella anläggningstillgångar och kortfristiga placeringar		-999 999	0
Räntekostnader och liknande resultatposter		-10 432	-4 826
Summa finansiella poster		-1 606 109	-4 826
Resultat efter finansiella poster		-1 407 359	637 738
Bokslutsdispositioner			
Förändring av periodiseringsfonder		0	-164 377
Summa bokslutsdispositioner		0	-164 377
Resultat före skatt		-1 407 359	473 361
Skatter			
Skatt på årets resultat		-45 985	-101 582
Årets resultat		-1 453 344	371 779

2025061014686

CJ Scandinavian Seaview Consulting AB

Org.nr. 559231-1657

BALANSRÄKNING**TILLGÅNGAR****Anläggningstillgångar****Finansiella anläggningstillgångar**

Andelar i koncernföretag

2

0

2 150 291

Andra långfristiga värdepappersinnehav

3

2 136 339

1 000 000

Summa finansiella anläggningstillgångar

2 136 339

3 150 291

Summa anläggningstillgångar

2 136 339

3 150 291

Omsättningstillgångar**Kortfristiga fordringar**

Kundfordringar

0

307 500

Övriga fordringar

767 603

787 383

Summa kortfristiga fordringar

767 603

1 094 883

Kassa och bank

Kassa och bank

267 869

480 692

Summa kassa och bank

267 869

480 692

Summa omsättningstillgångar

1 035 472

1 575 575

SUMMA TILLGÅNGAR**3 171 811****4 725 866**

2025061014687

CJ Scandinavian Seaview Consulting AB

Org.nr. 559231-1657

BALANSRÄKNING

2024-12-31

2023-12-31

Not

EGET KAPITAL OCH SKULDER**Eget kapital****Bundet eget kapital**

Aktiekapital

50 000

50 000

Summa bundet eget kapital

50 000

50 000

Fritt eget kapital

Balanserat resultat

3 594 639

3 222 860

Årets resultat

-1 453 344

371 779

Summa fritt eget kapital

2 141 295

3 594 639

Summa eget kapital

2 191 295

3 644 639

Obeskattade reserver

Periodiseringsfonder

934 531

934 531

Summa obeskattade reserver

934 531

934 531

Kortfristiga skulder

Skatteskulder

45 985

69 231

Övriga skulder

0

77 465

Summa kortfristiga skulder

45 985

146 696

SUMMA EGET KAPITAL OCH SKULDER

3 171 811

4 725 866

2025061014588

CJ Scandinavian Seaview Consulting AB

Org.nr. 559231-1657

NOTER**Not 1 Redovisnings- och värderingsprinciper**

Årsredovisningen är upprättad i enlighet med årsredovisningslagen och Bokföringsnämndens allmänna råd (BFNAR 2016:10) om årsredovisning i mindre företag.

Noter till balansräkningen**Not 2 Andelar i koncernföretag**

	2024-12-31	2023-12-31
Ingående anskaffningsvärden	2 150 291	1 810 276
Inköp	0	340 015
Försäljningar	-600 019	0
Omklassificeringar	-1 550 272	0
Utgående anskaffningsvärden	0	2 150 291
Redovisat värde	0	2 150 291


Not 3 Andra långfristiga värdepappersinnehav

	2024-12-31	2023-12-31
Ingående anskaffningsvärden	1 000 000	1 000 000
Inköp	586 066	0
Omklassificeringar	1 550 272	0
Utgående anskaffningsvärden	3 136 338	1 000 000
Årets nedskrivningar	-999 999	0
Utgående nedskrivningar	-999 999	0
Redovisat värde	2 136 339	1 000 000

Övriga noter**Not 4 Definition av nyckeltal**

Soliditet
Justerat eget kapital i procent av balansomslutning

Lund

Signé par:

3138C764BD9F45E...

Chenjie Xu
2025-03-26

Fotokopierat överensstämmande
med originalet intygas



Certificate Of Completion

Envelope Id: F42A6A52-7AD4-45B2-A0DA-1503847DD41B Status: Completed
 Subject: Complete with Docusign: ÅR 2024 CJ Scandinavian Seaview Consulting AB.pdf, ÅSP 2024 CJ Scandina...
 Source Envelope:
 Document Pages: 7 Signatures: 2 Envelope Originator:
 Certificate Pages: 4 Initials: 0 Anna Jönsson
 AutoNav: Enabled Stortorget 1
 EnvelopeId Stamping: Enabled Lund, Skåne 222 23
 Time Zone: (UTC+01:00) Amsterdam, Berlin, Bern, Rome, Stockholm, Vienna anna.jonsson@eqlpharma.com
IP Address: 10.111.40.7


Record Tracking

Status: Original Holder: Anna Jönsson Location: DocuSign
 4/29/2025 9:52:35 AM anna.jonsson@eqlpharma.com

Signer Events

Chenjie Xu
 chenjie.xu@eqlpharma.com
 Security Level: Email, Account Authentication (None)

Signature

Signé par :

 3138C764BD9F45E...

Signature Adoption: Pre-selected Style
 Using IP Address: 213.164.195.142

Timestamp

Sent: 4/29/2025 9:54:45 AM
 Resent: 5/14/2025 1:59:07 PM
 Resent: 5/30/2025 8:32:35 AM
 Viewed: 5/30/2025 11:55:04 AM
 Signed: 5/30/2025 11:56:53 AM

Electronic Record and Signature Disclosure:
 Accepted: 5/30/2025 11:55:04 AM
 ID: c69e8950-3c05-48d4-8f61-cf9fd79de7a0

In Person Signer Events

Signature

Timestamp

Editor Delivery Events

Status

Timestamp

Agent Delivery Events

Status

Timestamp

Intermediary Delivery Events

Status

Timestamp

Certified Delivery Events

Status

Timestamp

Carbon Copy Events

Status

Timestamp

Witness Events

Signature

Timestamp

Notary Events

Signature

Timestamp

Envelope Summary Events

Status

Timestamps

Envelope Sent	Hashed/Encrypted	4/29/2025 9:54:45 AM
Certified Delivered	Security Checked	5/30/2025 11:55:04 AM
Signing Complete	Security Checked	5/30/2025 11:56:53 AM
Completed	Security Checked	5/30/2025 11:56:52 AM

Payment Events

Status

Timestamps

Electronic Record and Signature Disclosure

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, EQL Pharma AB (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

2025061014692

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact EQL Pharma AB:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: Justyna.Kwiatkowska@eqlpharma.com

To advise EQL Pharma AB of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at Justyna.Kwiatkowska@eqlpharma.com and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from EQL Pharma AB

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to Justyna.Kwiatkowska@eqlpharma.com and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with EQL Pharma AB

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

2025061014693

i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;

ii. send us an email to Justyna.Kwiatkowska@eqlpharma.com and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-system-requirements>.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to ‘I agree to use electronic records and signatures’ before clicking ‘CONTINUE’ within the DocuSign system.

By selecting the check-box next to ‘I agree to use electronic records and signatures’, you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify EQL Pharma AB as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by EQL Pharma AB during the course of your relationship with EQL Pharma AB.